Psychosis as a treatment target in dementia: A roadmap for designing interventions

Manuscript Number: 

21-5483R2

Author(s): 
Luis Agüera-Ortiz, Ganesh M. Babulal, Marie-Andrée Bruneau, Byron Creese, Fabrizia D'Antonio, Corinne E. Fischer, Jennifer R. Gatchel, Zahinoor Ismail, Sanjeev Kumar, Krista L. Lanctôt, William Jonathan McGeown, Moyra E. Mortby, Nicolas Nuñez, Fabricio Ferreira de Oliveira, Arturo X. Pereiro, Ramit Ravona-Springer, Hillary J. Rouse, Huali Wang

Disclosures

Luis Agüera-Ortiz

  • Consulting Fees:
    Paid advisory board once a year: Exeltis
    Lecture Fees:
    Medical educational activities: Janssen, Lundbeck, Neuraxpharm, Exeltis and Angelini.

Ganesh M. Babulal

  • Nothing to Disclose

Marie-Andrée Bruneau

  • Nothing to Disclose

Byron Creese

  • Nothing to Disclose

Fabrizia D'Antonio

  • Nothing to Disclose

Corinne E. Fischer

  • Grants
    • Agency: 
      Hoffman La Roche
      Dates: 
      2019-2022
    • Agency: 
      Vielight Incorporated
      Dates: 
      2019-2022

Jennifer R. Gatchel

  • Nothing to Disclose

Zahinoor Ismail

  • Consulting Fees:
    Consulting to Otsuka/Lundbeck outside the submitted work

Sanjeev Kumar

  • Nothing to Disclose

Krista L. Lanctôt

  • Consulting Fees:
    Consultant/Advisor Role(s): BioXcel Therapeutics, Bright Minds Biosciences, Cerevel Therapeutics, Eisai, GW Bioscience, ICG Pharma, Kondor Pharma, Lundbeck, Merck, Novo Nordisk, Praxis, Sumitomo Pharm
    Equity:
    Highmark Interactive

William Jonathan McGeown

  • Nothing to Disclose

Moyra E. Mortby

  • Nothing to Disclose

Nicolas Nuñez

  • Nothing to Disclose

Fabricio Ferreira de Oliveira

  • Nothing to Disclose

Arturo X. Pereiro

  • Nothing to Disclose

Ramit Ravona-Springer

  • Nothing to Disclose

Hillary J. Rouse

  • Nothing to Disclose

Huali Wang

  • Nothing to Disclose